Related Experiment Video
Updated: Jun 16, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet therapies for the treatment of cardiovascular disease
1Center for Platelet Research Studies, Children's Hospital Boston, Karp 08213, 300 Longwood Avenue, Boston, Massachusetts 02115-5737, USA. alan.michelson@childrens.harvard.edu
Insights
Antiplatelet therapy effectively reduces mortality in heart attacks. New agents targeting platelet function show promise for further improving outcomes in cardiovascular disease.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Platelets play a critical role in hemostasis and cardiovascular thrombosis.
- Acute myocardial infarction (AMI) management benefits significantly from antiplatelet therapy.
- Understanding platelet molecular mechanisms drives new therapeutic development.
Purpose of the Study:
- To review the role of platelets in hemostasis and cardiovascular thrombosis.
- To discuss current and investigational antiplatelet agents for cardiovascular disease.
- To analyze the benefits and limitations of these antiplatelet therapies.
Main Methods:
- Literature review of platelet function in thrombosis.
- Analysis of clinical data on antiplatelet agents in cardiovascular disease.
- Discussion of emerging antiplatelet drug mechanisms and trials.
Main Results:
- Antiplatelet therapy is established in reducing AMI mortality and morbidity.
- Novel antiplatelet agents offer potential for enhanced risk reduction.
- Current agents have established benefits but also limitations.
Conclusions:
- Platelet inhibition remains a cornerstone in cardiovascular disease management.
- Investigational antiplatelet agents represent a promising frontier.
- Balancing efficacy and safety is crucial for optimizing antiplatelet strategies.
Abstract:
Antiplatelet therapy has been successful in reducing mortality and morbidity in acute myocardial infarction. Recent advances in understanding the molecular basis of the role of platelets in cardiovascular thrombosis have enabled the development of new agents with the potential to further reduce mortality and morbidity. This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care

